TNF Alpha Small-Molecule Modulators for Permeability and Cardiac Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for TNF alpha-mediated disorders rely on macromolecular inhibitors, which are limited in their application and effectiveness for a wide range of conditions including autoimmune, inflammatory, neurological, neurodegenerative, pain, cardiovascular, metabolic, ocular, and oncological disorders.
Innovation Solution
Development of small molecule modulators, represented by compounds of Formula (I*) and their pharmaceutically acceptable salts or stereoisomers, to regulate TNF alpha activity, offering improved potency, reduced cardiac toxicity, enhanced cell permeability, and better pharmacokinetic and pharmacodynamic properties compared to benzimidazole core compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If macromolecular TNF alpha inhibitors are used, then TNF alpha binding inhibition is achieved, but application effectiveness for wide range of conditions is limited
Solution Approach 1:
The patent transitions from macromolecular inhibitors to small molecule modulators, fundamentally changing the molecular size and structural parameters. This enables the compounds to penetrate cell membranes and intracellular compartments, expanding their applicability to conditions requiring intracellular TNF alpha modulation while maintaining receptor binding inhibition capability
2Ease of operation
If small molecule modulators are developed, then cell permeability is enhanced, but cardiac toxicity may increase
Solution Approach 1:
The patent employs specific structural modifications at localized positions within the molecule. The core structure features distinct substituent patterns at different positions (R1, R2, R3, R4 groups) that independently control different properties: some regions enhance cell permeability while others reduce cardiac toxicity, allowing simultaneous optimization of multiple properties through localized structural control
Solution Approach 2:
The small molecule modulators utilize composite structural elements combining heteroaryl cores with various substituent groups. This composite approach allows integration of multiple functional characteristics within a single molecule, achieving both enhanced cell permeability and reduced cardiac toxicity through synergistic structural design
3Reliability
If small molecule modulators are used, then potency is improved, but manufacturing complexity increases
Solution Approach 1:
The patent structures the small molecule modulators with segmented, modular components including a core heteroaryl structure and distinct substituent groups (R1, R2, R3, R4). This segmentation allows independent optimization of each component for potency while simplifying manufacturing, as each segment can be synthesized separately and assembled through well-established organic chemistry techniques
Data Source
AI summary
Described herein are modulators of TNF alpha activity and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of TNF alpha-mediated disorders or diseases.